'Quantamental' Japan Specialist, LightStream Research

Campbell Gunn

'Quantamental' Japan Specialist

Long-Short Analysis on Japan, Asia and the World

LightStream Research

LightStream conducts quantitatively rigorous and data-driven analysis with a focus on Japan and Asia.

We consistently cover the Tech, Consumer and Industrial sectors, and provide ECM and Events coverage more broadly.

We supplement traditional qualitative insights from company relationships with a robust quantitative foundation that examines as much historical data as is available.
We further refine the accuracy of our insights and calls through the use of alternative data to flesh out current trends, and through a valuation framework that emphasises non-superficial peer group selection and a proper attempt to understand the metrics and changes that have driven security valuations in the past.

Thematic (Sector/Industry)

<div class="content-highlight"><p style="text-align: center;"><strong><em>"Beware of geeks bearing formulas." - Warren Buffett </em></strong></p></div><p>Enterprise Value multiples have become common parlance in the investment world, both <strong>Enterprise Value/Operating Profit</strong> (EV/OP or EV/EBIT) and it's flawed 'bastard' cousin EV/EBITDA which we will leave well alone for this Insight. With markets supported on a cloud of central bank's liquidity and corporate trailing earnings distorted by COVID-19, many valuation ratios appear meaningless. To inject a dose of reality into the analysis of Japanese corporate valuations, we have created a new metric -<strong> Enterprise Value/Peak Operating Profit (EV/POP).</strong></p><figure class="editor-figure mceNonEditable"><img src="https://static-prod.smartkarma.com/images/media/000/155/071/original/2020-08-26_10-36-07.png?1598405812" class="editor-image img-responsive" data-smartkarma-image-id="155071"></figure><div class="content-caption">Source: Japan Analytics (applies to all charts below)</div><p><strong>EV &amp; OP TIMELINE</strong> - Using currently-listed non-financial companies (with the four exceptions noted in the legend above), the correlation between Enterprise Value (here divided by 10) and Operating Income has increased since 2013. However, the current positive EV&lt;&gt;OP 'spread' is now larger than at any time since 2002. While non-financial Operating Profits have declined by 22% since peaking in the first quarter of FY2019, Enterprise Value is just ¥2.9 trillion, or 5% below its <a href="mailto:FY18-@Q" target="_blank" rel="noopener">FY18-</a>2Q peak level. Where the lines converge, the EV/OP multiple is 10 times, which is close to the sixteen-year average and the arbitrary line we shall use to distinguish the overvalued from the undervalued. </p><figure class="editor-figure mceNonEditable"><img src="https://static-prod.smartkarma.com/images/media/000/155/075/original/2020-08-26_10-56-07.png?1598406979" class="editor-image img-responsive" data-smartkarma-image-id="155075"></figure><p><strong>EV/OP &amp; EV/POP</strong> - Aggregate EV/OP is now 11.6 times, breaking out of a narrow range to reach a  new a ten-year high. EV/POP reached a five-year low in March of 7.9 times but is now 20 basis points above the seven-year average of 8.8 times. By neither measure could the market be considered cheap; however, in EV/POP terms, aggregate valuations are only just above average.  For several favoured companies for which the market is prepared to pay any price for their perceived quality EV/POP multiple are far from average as in the examples below. At the other end of the valuation spectrum, EV/POP reveals some clear bargain-hunting opportunities.</p><figure class="editor-figure mceNonEditable"><img src="https://static-prod.smartkarma.com/images/media/000/155/100/original/2020-08-26_13-12-11.png?1598415140" class="editor-image img-responsive" data-smartkarma-image-id="155100"></figure><figure class="editor-figure mceNonEditable"><img src="https://static-prod.smartkarma.com/images/media/000/155/102/original/2020-08-26_13-12-39.png?1598415169" class="editor-image img-responsive" data-smartkarma-image-id="155102"></figure><figure class="editor-figure mceNonEditable"><img src="https://static-prod.smartkarma.com/images/media/000/155/104/original/2020-08-26_13-15-58.png?1598415375" class="editor-image img-responsive" data-smartkarma-image-id="155104"></figure><p>In the <strong>DETAIL</strong> section, we look at the non-financial companies at more examples from both extremes of this metric, in an attempt to pick potential winners and losers as the world slowly normalises and liquidity begins to ebb.  We have purposely excluded companies with negative Enterprise Values, which we shall cover in a upcoming Insight. We have also excluded companies that have listed only in the last four years.</p>

"Beware of geeks bearing formulas." - Warren Buffett Enterprise Value multiples have become common parlance in the investment world, both Enterprise Value/Operating Profit (EV/OP or EV/EBIT) and it's flawed 'bastard' cousin EV/EBITDA which we will leave well alone for this Insight. With markets supported on a cloud of central bank's liquidity and corporate trailing earnings distorted by COVID-19, many valuation ratios appear meaningless. To inject a dose of reality into the analysis of Japanese corporate valuations, we have created a new metric - Enterprise Value/Peak Operating Profit (EV/POP).Source: Japan Analytics (applies to all charts below)EV &amp; OP TIMELINE - Using currently-listed non-financial companies (with the four exceptions noted in the legend above), the correlation between Enterprise Value (here divided by 10) and Operating Income has increased since 2013. However, the current positive EV&lt;&gt;OP 'spread' is now larger than at any time since 2002. While non-financial Operating Profits have declined by 22% since peaking in the first quarter of FY2019, Enterprise Value is just ¥2.9 trillion, or 5% below its FY18-2Q peak level. Where the lines converge, the EV/OP multiple is 10 times, which is close to the sixteen-year average and the arbitrary line we shall use to distinguish the overvalued from the undervalued. EV/OP &amp; EV/POP - Aggregate EV/OP is now 11.6 times, breaking out of a narrow range to reach a  new a ten-year high. EV/POP reached a five-year low in March of 7.9 times but is now 20 basis points above the seven-year average of 8.8 times. By neither measure could the market be considered cheap; however, in EV/POP terms, aggregate valuations are only just above average.  For several favoured companies for which the market is prepared to pay any price for their perceived quality EV/POP multiple are far from average as in the examples below. At the other end of the valuation spectrum, EV/POP reveals some clear bargain-hunting opportunities.In the DETAIL section, we look at the non-financial companies at more examples from both extremes of this metric, in an attempt to pick potential winners and losers as the world slowly normalises and liquidity begins to ebb.  We have purposely excluded companies with negative Enterprise Values, which we shall cover in a upcoming Insight. We have also excluded companies that have listed only in the last four years.

🇯🇵 JAPAN • Stock Picking with 'Peak' EV/OP Multiples - Introducing EV/POP

Equity Analyst, LightStream Research

Shifara Samsudeen, ACMA, CGMA

Equity Analyst

Equity Bottom-Up

<p>Terumo reported its 1QFY03/2021 results on Thursday (06<sup>th</sup> August 2020) which saw both revenue and operating profit declining YoY by 14% and 38% respectively. Although revenues from the cardiac and vascular segment and general hospital segment declined, the blood and cell technology segment managed to grow its revenue by a marginal 2% YoY.</p><p>The reported revenue was 4.2% below consensus estimates, however, the company managed to beat consensus on operating profit by 4.2% during the quarter.</p><table class="table table-striped"><tbody>
<tr>
<td style="width: 49.75pt;"><p style="text-align: center;"><strong>JPY (bn)</strong></p></td>
<td style="width: 72.9pt;"><p style="text-align: center;"><strong>1QFY03/2020</strong></p></td>
<td style="width: 72.9pt;"><p style="text-align: center;"><strong>1QFY03/2021</strong></p></td>
<td style="width: 44.95pt;"><p style="text-align: center;"><strong>% YoY</strong></p></td>
<td style="width: 58.95pt;"><p style="text-align: center;"><strong>Consensus</strong></p></td>
<td style="width: 75.7pt;"><p style="text-align: center;"><strong>Actual v Consensus</strong></p></td>
</tr>
<tr>
<td style="width: 49.75pt;"><p>Revenue</p></td>
<td style="width: 72.9pt;"><p style="text-align: right;">152.5</p></td>
<td style="width: 72.9pt;"><p style="text-align: right;">131.3</p></td>
<td style="width: 44.95pt;"><p style="text-align: right;">-13.9%</p></td>
<td style="width: 58.95pt;"><p style="text-align: right;">137.0</p></td>
<td style="width: 75.7pt;"><p style="text-align: right;">-4.2%</p></td>
</tr>
<tr>
<td style="width: 49.75pt;"><p>OP</p></td>
<td style="width: 72.9pt;"><p style="text-align: right;">29.2</p></td>
<td style="width: 72.9pt;"><p style="text-align: right;">18.1</p></td>
<td style="width: 44.95pt;"><p style="text-align: right;">-38.0%</p></td>
<td style="width: 58.95pt;"><p style="text-align: right;">17.4</p></td>
<td style="width: 75.7pt;"><p style="text-align: right;">4.2%</p></td>
</tr>
<tr>
<td style="width: 49.75pt;"><p>OPM</p></td>
<td style="width: 72.9pt;"><p style="text-align: right;">19.1%</p></td>
<td style="width: 72.9pt;"><p style="text-align: right;">13.8%</p></td>
<td style="width: 44.95pt;"><p> </p></td>
<td style="width: 58.95pt;"><p style="text-align: right;">12.7%</p></td>
<td style="width: 75.7pt;"><p> </p></td>
</tr>
</tbody></table><div class="content-caption"><em>Source: Company disclosures, CapIQ</em></div><p>The decline in revenue was mainly due to the sharp decline in Terumo’s largest segment, cardiac and vascular.</p><figure class="editor-figure mceNonEditable"><img src="https://static-prod.smartkarma.com/images/media/000/151/551/original/image_21426346931596998931586.png?1596998934" class="editor-image img-responsive" data-smartkarma-image-id="151551"></figure><div class="content-caption"><em>Source: Company disclosures</em></div>

Terumo reported its 1QFY03/2021 results on Thursday (06th August 2020) which saw both revenue and operating profit declining YoY by 14% and 38% respectively. Although revenues from the cardiac and vascular segment and general hospital segment declined, the blood and cell technology segment managed to grow its revenue by a marginal 2% YoY.The reported revenue was 4.2% below consensus estimates, however, the company managed to beat consensus on operating profit by 4.2% during the quarter.

JPY (bn)
1QFY03/2020
1QFY03/2021
% YoY
Consensus
Actual v Consensus


Revenue
152.5
131.3
-13.9%
137.0
-4.2%


OP
29.2
18.1
-38.0%
17.4
4.2%


OPM
19.1%
13.8%
 
12.7%
 

Source: Company disclosures, CapIQThe decline in revenue was mainly due to the sharp decline in Terumo’s largest segment, cardiac and vascular.Source: Company disclosures

Terumo: Pandemic Impacts Q1 but Recovery Is Expected in the 2nd Half

<p style="text-align: center;"><strong>•BEST &amp; WORST 6th AUGUST •</strong></p><p style="text-align: left;">The 'best' and 'worst' from yesterday's large-cap announcements came from <a href="https://www.smartkarma.com/entities/square-enix-holdings-co-ltd" target="_blank" data-smartkarma-citation="entities:15003:1" rel="noopener">Square Enix (9684 JP)</a> and <a href="https://www.smartkarma.com/entities/shiseido-company-limited" target="_blank" data-smartkarma-citation="entities:5718:1" rel="noopener">Shiseido (4911 JP)</a>, respectively - the latter as flagged in <a href="https://www.smartkarma.com/insights/shiseido-4911-jp-downward-revision-imminent" target="_blank" data-smartkarma-citation="insights:41874" rel="noopener">Downward Revision Imminent</a>  More extensive coverage follows in the DETAIL section below.</p><figure class="editor-figure mceNonEditable"><img src="https://static-prod.smartkarma.com/images/media/000/151/081/original/2020-08-07_05-30-09.png?1596745840" class="editor-image img-responsive" data-smartkarma-image-id="151081"></figure><figure class="editor-figure mceNonEditable"><img src="https://static-prod.smartkarma.com/images/media/000/151/082/original/2020-08-07_05-31-27.png?1596745907" class="editor-image img-responsive" data-smartkarma-image-id="151082"></figure><div style="text-align: center;" class="content-caption">Source • Japan Analytics<hr>
</div><p></p><div><p style="text-align: center;"><strong>DAILY STATS</strong></p></div><hr><div><p><strong>PERCENTAGES</strong> -<strong> 64%</strong> of quarterly results,  <strong>78%</strong> of annual forecasts/revisions and<strong> 79%</strong> of interim forecasts have negative Scores and <strong>28%</strong> of companies reporting lost money for the quarter.</p></div><hr><div><p style="text-align: center;"><strong>332 Quarterly Results</strong></p></div><div><ul>
<li>
<strong>Results Score: </strong>29% Positive / 7% Neutral / 64% Negative</li>
<li>
<strong>Average Results Score Change:</strong> -3.0 points</li>
<li>
<strong>Average % Change in Revenue: </strong>-9.7% Quarter YoY / -3.5% Rolling TTM YoY </li>
<li>
<strong>Average Operating Profit Margin Change:</strong> -0.7 ppt</li>
<li>
<strong>Percentage Making Quarterly Losses:</strong> 28%</li>
</ul></div><hr><div><p style="text-align: center;"><strong>121 Annual • 76 Interim Forecasts/Revisions</strong></p></div><div><ul>
<li>
<strong>Annual Forecast/Revision Score:</strong> 17% Positive / 6% Neutral / 78% Negative</li>
<li>
<strong>Interim Forecast/Revision Score Change:</strong> 17% Positive / 4% Neutral / 79% Negative</li>
<li>
<strong>Average Forecast/Revision Score Change:</strong> -11.2 points</li>
</ul></div>

•BEST &amp; WORST 6th AUGUST •The 'best' and 'worst' from yesterday's large-cap announcements came from Square Enix (9684 JP) and Shiseido (4911 JP), respectively - the latter as flagged in Downward Revision Imminent  More extensive coverage follows in the DETAIL section below.Source • Japan Analytics
DAILY STATSPERCENTAGES - 64% of quarterly results,  78% of annual forecasts/revisions and 79% of interim forecasts have negative Scores and 28% of companies reporting lost money for the quarter.332 Quarterly Results

Results Score: 29% Positive / 7% Neutral / 64% Negative

Average Results Score Change: -3.0 points

Average % Change in Revenue: -9.7% Quarter YoY / -3.5% Rolling TTM YoY 

Average Operating Profit Margin Change: -0.7 ppt

Percentage Making Quarterly Losses: 28%
121 Annual • 76 Interim Forecasts/Revisions

Annual Forecast/Revision Score: 17% Positive / 6% Neutral / 78% Negative

Interim Forecast/Revision Score Change: 17% Positive / 4% Neutral / 79% Negative

Average Forecast/Revision Score Change: -11.2 points


🇯🇵 JAPAN • Results & Revisions 6th August - Nintendo, Yamada Denki, Terumo, Toyota, Shiseido

<figure class="editor-figure mceNonEditable"><img src="https://static-prod.smartkarma.com/images/media/000/134/299/original/2020-05-19_06-46-49.png?1589838438" class="editor-image img-responsive" data-smartkarma-image-id="134299"></figure><div class="content-caption">Source • Japan Analytics</div><div><p>As this quarter's results and revisions announcements wind down, in the<strong> DETAIL</strong> below, we shall review Monday's updates:-</p></div><div><ul>
<li>The balance between positive/neutral/negative of the <strong>50</strong> results announcements was <strong>23:2:25</strong>. </li>
<li>For the <strong>24</strong> revisions/initial forecasts, the split was <strong>6:0:18</strong>, and the average Revision Score was <strong>-6.1</strong>. </li>
</ul></div>

Source • Japan AnalyticsAs this quarter's results and revisions announcements wind down, in the DETAIL below, we shall review Monday's updates:-
The balance between positive/neutral/negative of the 50 results announcements was 23:2:25. 
For the 24 revisions/initial forecasts, the split was 6:0:18, and the average Revision Score was -6.1. 


🇯🇵 JAPAN • Results & Revisions 18th May - Panasonic, Komatsu, Terumo, Sundrug & The Corona Valley

<figure class="editor-figure mceNonEditable"><img src="https://static-prod.smartkarma.com/images/media/000/133/748/original/2020-05-16_08-18-15.png?1589584720" class="editor-image img-responsive" data-smartkarma-image-id="133748"></figure><div class="content-caption">Source • Japan Analytics</div><p><strong>"WORSENING"</strong> - The Cabinet Office updated their Business Condition Leading Indicator for March this week, confirming the trend already apparent from our Results &amp; Revision Score data series. The correlation between the series is 0.80, with the only significant deviation occurring in 2016, Coincident conditions are assessed as "worsening" wording that is unchanged since August 2019. </p><figure class="editor-figure mceNonEditable"><img src="https://static-prod.smartkarma.com/images/media/000/133/788/original/2020-05-16_12-10-50.png?1589598664" class="editor-image img-responsive" data-smartkarma-image-id="133788"></figure><div class="content-caption">Source • Japan Analytics</div><p><strong>DECOMPOSED</strong> - Our Score is decomposed into a Results Score, an Annual Forecast/Revision Score and an Interim Forecast Revision Score.  The last two are ten-year lows; the first should join them next week. A notable limiting factor is the shortage of forecasts being made. Without this reticence, both forecast Scores would be considerably lower.</p><figure class="editor-figure mceNonEditable"><img src="https://static-prod.smartkarma.com/images/media/000/133/795/original/2020-05-16_12-47-02.png?1589600841" class="editor-image img-responsive" data-smartkarma-image-id="133795"></figure><div class="content-caption">Source • Japan Analytics</div><p><strong>RETICENCE</strong> - 77% by number and 81% by value of companies with year-ends in  March, June, September, or December have already reported. Of these 2,464 companies representing ¥438 trillion of market cap, just 1,119 have issued annual forecasts for the current year, and 583 have made interim forecasts. Of all listed companies, one-third by market value are currently unable to see ahead twelve months and only 16% by value and 23% by number are prepared to look forward four-and-a-half months. This unusual degree of reticence leaves the sell-side without their regular anchoring comfort blanket.</p><figure class="editor-figure mceNonEditable"><img src="https://static-prod.smartkarma.com/images/media/000/133/802/original/2020-05-16_13-27-57.png?1589605282" class="editor-image img-responsive" data-smartkarma-image-id="133802"></figure><div class="content-caption">Source • Japan Analytics</div><p><strong>NOT CHEAP</strong> -  Even allowing for the lack of a full complement of forecasts, the market's forward multiple is at a five-year high with Net Income expected to reach levels first seen in 2015, 37% below the December 2018 peak. The ten-year peak trailing multiple was 29 on aggregate Net Income of  ¥14.6 trillion, which was ten times the 2009 trough.</p><figure class="editor-figure mceNonEditable"><img src="https://static-prod.smartkarma.com/images/media/000/133/801/original/2020-05-16_14-00-16.png?1589605245" class="editor-image img-responsive" data-smartkarma-image-id="133801"></figure><div class="content-caption">Source • Japan Analytics</div><p><strong>FIDDLING ABOUT</strong> - The Bank of Japan has reduced the amount of its daily ETF program for a second time; however, intervened for the last three days of last week seemingly intent on keeping the <a href="https://www.smartkarma.com/entities/nikkei-225" target="_blank" data-smartkarma-citation="entities:22909:1" rel="noopener">Nikkei 225 (NKY INDEX)</a> above 20,000. The cumulative total of BoJ purchases represents over 5% of the Total Market Value.</p><figure class="editor-figure mceNonEditable"><img src="https://static-prod.smartkarma.com/images/media/000/133/884/original/2020-05-17_12-54-22.png?1589687679" class="editor-image img-responsive" data-smartkarma-image-id="133884"></figure><div class="content-caption">Source • Japan Analytics</div><p>In the <strong>DETAIL</strong> below, we review some market data trends, look at the Results &amp; Revision Score trends by Sector (a 15-year timeline is shown above), apply some KPMG 'recovery analysis' to Japan and look at Friday's results and revisions.</p><div><ul>
<li>The balance between positive/neutral/negative of the <strong>490</strong> results announcements was <strong>206:45:239</strong>. The average change in Results Score was <strong>-0.2</strong>.</li>
<li>For the <strong>205</strong> revisions/initial forecasts, the split was <strong>49:10:146</strong>, and the average Revision Score was <strong>-7.5</strong>. Of the <strong>364</strong> companies declaring full-year results, <strong>47%</strong> made forecasts for the current year.</li>
<li>Fifty-one will announce today, the largest of which by market capitalisation will be <a href="https://www.smartkarma.com/entities/softbank-group-corp" target="_blank" data-smartkarma-citation="entities:315:1" rel="noopener">Softbank Group (9984 JP)</a>, <a href="https://www.smartkarma.com/entities/terumo-corp" target="_blank" data-smartkarma-citation="entities:6708:1" rel="noopener">Terumo Corp (4543 JP)</a>, and <a href="https://www.smartkarma.com/entities/komatsu-ltd" target="_blank" data-smartkarma-citation="entities:8416:1" rel="noopener">Komatsu (6301 JP).</a>
</li>
</ul></div>

Source • Japan Analytics"WORSENING" - The Cabinet Office updated their Business Condition Leading Indicator for March this week, confirming the trend already apparent from our Results &amp; Revision Score data series. The correlation between the series is 0.80, with the only significant deviation occurring in 2016, Coincident conditions are assessed as "worsening" wording that is unchanged since August 2019. Source • Japan AnalyticsDECOMPOSED - Our Score is decomposed into a Results Score, an Annual Forecast/Revision Score and an Interim Forecast Revision Score.  The last two are ten-year lows; the first should join them next week. A notable limiting factor is the shortage of forecasts being made. Without this reticence, both forecast Scores would be considerably lower.Source • Japan AnalyticsRETICENCE - 77% by number and 81% by value of companies with year-ends in  March, June, September, or December have already reported. Of these 2,464 companies representing ¥438 trillion of market cap, just 1,119 have issued annual forecasts for the current year, and 583 have made interim forecasts. Of all listed companies, one-third by market value are currently unable to see ahead twelve months and only 16% by value and 23% by number are prepared to look forward four-and-a-half months. This unusual degree of reticence leaves the sell-side without their regular anchoring comfort blanket.Source • Japan AnalyticsNOT CHEAP -  Even allowing for the lack of a full complement of forecasts, the market's forward multiple is at a five-year high with Net Income expected to reach levels first seen in 2015, 37% below the December 2018 peak. The ten-year peak trailing multiple was 29 on aggregate Net Income of  ¥14.6 trillion, which was ten times the 2009 trough.Source • Japan AnalyticsFIDDLING ABOUT - The Bank of Japan has reduced the amount of its daily ETF program for a second time; however, intervened for the last three days of last week seemingly intent on keeping the Nikkei 225 (NKY INDEX) above 20,000. The cumulative total of BoJ purchases represents over 5% of the Total Market Value.Source • Japan AnalyticsIn the DETAIL below, we review some market data trends, look at the Results &amp; Revision Score trends by Sector (a 15-year timeline is shown above), apply some KPMG 'recovery analysis' to Japan and look at Friday's results and revisions.
The balance between positive/neutral/negative of the 490 results announcements was 206:45:239. The average change in Results Score was -0.2.
For the 205 revisions/initial forecasts, the split was 49:10:146, and the average Revision Score was -7.5. Of the 364 companies declaring full-year results, 47% made forecasts for the current year.
Fifty-one will announce today, the largest of which by market capitalisation will be Softbank Group (9984 JP), Terumo Corp (4543 JP), and Komatsu (6301 JP).



🇯🇵 JAPAN MARKET UPDATE 18th May - "Worsening"

Japan

TERUMO CORPORATION is a manufacturer and supplier of pharmaceuticals and medical tools and equipment.  The Company's products include health foods, transfusion and infusion equipment, disposable medical supply, clinical testing systems, artificial organs, and electronic thermometers.  Terumo markets the products through its subsidiaries and sales offices in the US, Europe, and Asia.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Terumo Corp (4543 JP)

🇯🇵 JAPAN • Stock Picking with 'Peak' EV/OP Multiples - Introducing EV/POP

"Beware of geeks bearing formulas." - Warren Buffett Enterprise Value multiples have become common parlance in the investment world, both...

Campbell Gunn

Terumo: Pandemic Impacts Q1 but Recovery Is Expected in the 2nd Half

Terumo reported its 1QFY03/2021 results on Thursday (06th August 2020) which saw both revenue and operating profit declining YoY by 14% and 38%...

Shifara Samsudeen, ACMA, CGMA

🇯🇵 JAPAN • Results & Revisions 6th August - Nintendo, Yamada Denki, Terumo, Toyota, Shiseido

•BEST & WORST 6th AUGUST •The 'best' and 'worst' from yesterday's large-cap announcements came from Square Enix (9684 JP) and Shiseido (4911...

Campbell Gunn

🇯🇵 JAPAN • Results & Revisions 18th May - Panasonic, Komatsu, Terumo, Sundrug & The Corona Valley

As this quarter's results and revisions announcements wind down, in the DETAIL below, we shall review Monday's updates:- The balance between...

Campbell Gunn

🇯🇵 JAPAN MARKET UPDATE 18th May - "Worsening"

"WORSENING" - The Cabinet Office updated their Business Condition Leading Indicator for March this week, confirming the trend already apparent from...

Campbell Gunn

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)